Integrative review reveals mechanisms of checkpoint inhibitor resistance in cancer, highlighting precision immuno-oncology strategies to improve durable benefit.
Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, CTLA-4, and LAG-3 have transformed cancer therapy, but resistance limits durable benefit. This integrative review summarizes primary, adaptive, and acquired resistance driven by tumor-intrinsic defects, suppressive tumor microenvironmental programs, and host-related factors. We discuss mechanism-based strategies to overcome resistance, including combination immunotherapy, antiangiogenic treatment, TGF-β targeting, myeloid reprogramming, epigenetic and metabolic interventions, microbiome modulation, and cellular or vaccine-based approaches. The findings support a precision immuno-oncology framework based on composite biomarkers, longitudinal monitoring, and adaptive treatment selection matched to dominant resistance mechanisms.
No takes yet. Share an insight, caveat, or question.
Lotfi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: